US COVID-19 Vaccination Rollout On Track After Early Bumps, J.P. Morgan Panelists Say
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
You may also be interested in...
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.
The speed of the new messenger RNA platforms could once again come to the rescue, but the expectation is that existing vaccines should remain effective against the emerging strain.
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.